華潤雙鶴(600062.SH):子公司的氨氯地平阿託伐他汀鈣片、枸櫞酸西地那非片獲批生產
格隆匯11月1日丨華潤雙鶴(600062.SH)公佈,近日,公司全資子公司華潤賽科藥業有限責任公司(“華潤賽科”)收到了國家藥品監督管理局頒發的氨氯地平阿託伐他汀鈣片、枸櫞酸西地那非片《藥品註冊證書》(證書編號分別為:2021S01083、2021S01088),批准該等藥品生產。
氨氯地平阿託伐他汀鈣片適用於需氨氯地平和阿託伐他汀聯合治療的患者。其中,氨氯地平用於高血壓的治療,用於慢性穩定性心絞痛、血管痙攣性心絞痛(Prinzmetal’s或變異型心絞痛)及經血管造影證實的冠心病的治療;阿託伐他汀用於高膽固醇血癥及冠心病的治療。
截至公吿日,公司針對氨氯地平阿託伐他汀鈣片累計研發投入為人民幣1570.37萬元(未經審計)。根據米內網數據顯示,2020年氨氯地平阿託伐他汀鈣片銷售總額(終端價)為7.96億元人民幣,瀚暉製藥有限公司(原為海正輝瑞製藥有限公司)佔100%市場份額。
枸櫞酸西地那非片適用於治療勃起功能障礙。截至公吿日,公司針對枸櫞酸西地那非片累計研發投入為人民幣1,042.68萬元(未經審計)。
根據全球71國家藥品銷售數據庫顯示,2020年,枸櫞酸西地那非片全球銷售額為16.24億美元。其中,“VIAGRA”全球銷售額為4.34億美元。
國內市場,根據國家藥監局網站信息顯示,中國大陸境內已批准上市的枸櫞酸西地那非片生產企業11家。根據米內網數據顯示,2020年枸櫞酸西地那非片銷售總額(終端價)為8724萬元人民幣,其中市場份額排名前5的企業分別為輝瑞製藥有限公司90.14%,江蘇亞邦愛普森藥業有限公司3.69%,廣州白雲山醫藥集團股份有限公司3.36%,齊魯製藥有限公司2.05%,地奧集團成都藥業股份有限公司0.74%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.